Abstract 30P
Background
Metastatic breast cancer (mBC) remains a leading cause of cancer-related deaths among women globally. Despite advances, many treatments fail to improve patient outcomes, emphasizing the need for innovative approaches and reliable biomarkers to better predict treatment response. Recent studies show that neutrophils play a critical role in cancer, with low density neutrophils (LDN) acting as key modulators in the tumor microenvironment. LDN are linked to tumor growth and metastasis, contributing to an immunosuppressive environment that supports cancer progression. Here, we investigated the clinical significance of LDN in breast cancer (BC) by assessing their association with disease progression and patient outcomes.
Methods
We analysed blood samples from 146 BC patients (78 non-metastatic, 68 metastatic), isolating both LDN and high-density neutrophils (HDN, conventional neutrophils) by density gradient centrifugation. Flow cytometry was used to quantify and characterize the populations.
Results
Our results show significant LDN accumulation in BC patients’ blood, particularly those with metastatic disease. Importantly, elevated LDN levels were linked to reduced life expectancy in these patients, regardless of metastatic site (bone, lung or brain). Moreover, the increase in LDN levels was often accompanied by a decrease in HDN, leading to an imbalance favoring protumor neutrophils. Additionally, preliminary data from a small cohort of triple-negative BC patients (n=7, ongoing recruitment) undergoing immunotherapy suggest that higher pre-treatment LDN levels may predict poorer treatment response. This early finding points to LDN’ potential as predictive biomarkers for immunotherapy efficacy in BC.
Conclusions
Our study highlights the prognostic value of LDN in BC, with elevated levels linked to advanced disease and worse clinical outcomes. These findings suggest that LDN could serve as valuable biomarkers for monitoring disease progression and predict treatment response, identifying patients at greater risk. Ultimately, incorporating LDN assessment into clinical practice may guide treatment strategies, offering a more personalized approach to BC management and potentially improving therapeutic outcomes.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
110P - Safety and effectiveness of adebrelimab as first-line treatment in extensive-stage small-cell lung cancer: A prospective, real-world study
Presenter: Junxu Wen
Session: Poster Display session
Resources:
Abstract
111P - Real-world treatment patterns and clinical outcomes in Chinese stage III non-small cell lung cancer (NSCLC) patients: Results of MOOREA study
Presenter: Ligang Xing
Session: Poster Display session
Resources:
Abstract
112P - Serplulimab combined with chemotherapy and anlotinib for extensive-stage small-cell lung cancer: A multicenter real-world experience
Presenter: Jun Wang
Session: Poster Display session
Resources:
Abstract
113P - Clinical outcomes of avelumab and pembrolizumab in advanced urothelial cancer: An observational multicenter retro-prospective study on patients undergoing treatment in clinical practice (AVePEm study)
Presenter: Irene Torresan
Session: Poster Display session
Resources:
Abstract
114P - Cadonilimab plus chemotherapy as first-line (1L) treatment for metastatic gastric (G) or gastroesophageal junction adenocarcinoma (GEJA) with PD-L1 CPS=5: Updated results from a real-world study
Presenter: Qi Xu
Session: Poster Display session
Resources:
Abstract
115P - Immune-related adverse events in cancer patients treated with immune checkpoint inhibitors in Germany: A population-based study
Presenter: Lucie Heinzerling
Session: Poster Display session
Resources:
Abstract
116TiP - An umbrella trial (RECHALLENGE) to evaluate the safety and preliminary efficacy of combination or sequential immunotherapy in advanced solid tumor patients after disease progression in clinical trials
Presenter: Huilei Miao
Session: Poster Display session
Resources:
Abstract
122P - Intracellular adenosine drives profound lymphocyte suppression and can be reversed with EOS-984: A potent ENT1 antagonist
Presenter: Erica Houthuys
Session: Poster Display session
Resources:
Abstract
123P - Combination potential of EO-3021, a CLDN18.2 vc-MMAE ADC, with VEGFR2 or PD1 inhibition in preclinical models of CLDN18.2-expressing cancers
Presenter: Thomas O'Hare
Session: Poster Display session
Resources:
Abstract
124P - AI-designed cancer vaccines: Antigens from the dark genome are promising cancer vaccine targets
Presenter: Daniela Kleine-Kohlbrecher
Session: Poster Display session
Resources:
Abstract